Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
RECRUITING
NCT06174766
PHASE3
A Study to Evaluate Efficacy and Safety of HGP2102 in Essential Hypertension Patients
Sponsor: Hanmi Pharmaceutical Company Limited
View on ClinicalTrials.gov
Summary
A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate the Efficacy and Safety of HGP2102 in patients with Essential Hypertension
Official title: A Multicenter, Randomized, Double-blind, Phase 3 Study to Evaluate Efficacy and Safety of HGP2102 in Patients With Essential Hypertension
Key Details
Gender
All
Age Range
19 Years - Any
Study Type
INTERVENTIONAL
Enrollment
324
Start Date
2024-05-10
Completion Date
2026-12-31
Last Updated
2025-06-12
Healthy Volunteers
No
Conditions
Interventions
DRUG
HGP2102-1
Test drug
DRUG
HGP2102-2
Test drug
DRUG
RLD2209-1
Control drug
DRUG
RLD2209-2
Control drug
Locations (1)
Sevrance hosptal
Seodaemun-gu, Seoul, South Korea